UCB's Global Corporate Website
Welcome to UCB in the United States
  • Healthcare Professionals
  • Patients
  • Investors
  • Dec

    08

    UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduced countable motor seizure frequency in CDKL5 deficiency disorder

    Dec

    04

    UCB shares leading scientific research and advances at American Epilepsy Society Annual Meeting

    Dec

    03

    Bridging Strategy and Innovation: Leadership in Action through the AES BRIDGE Program